NASDAQ:CTMX - CytomX Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $10.41 -0.73 (-6.55 %) (As of 03/24/2019 04:00 PM ET)Previous Close$10.41Today's Range$10.39 - $11.3752-Week Range$9.38 - $32.69Volume518,328 shsAverage Volume995,668 shsMarket Capitalization$469.60 millionP/E Ratio-5.13Dividend YieldN/ABeta0.7 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Receive CTMX News and Ratings via Email Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTMX Previous Symbol CUSIPN/A CIK1501989 Webwww.cytomx.com Phone650-515-3185Debt Debt-to-Equity RatioN/A Current Ratio4.55 Quick Ratio4.55Price-To-Earnings Trailing P/E Ratio-5.13 Forward P/E Ratio-4.78 P/E GrowthN/A Sales & Book Value Annual Sales$59.50 million Price / Sales7.89 Cash FlowN/A Price / Cash FlowN/A Book Value$2.91 per share Price / Book3.58Profitability EPS (Most Recent Fiscal Year)($2.03) Net Income$-84,600,000.00 Net Margins-142.19% Return on Equity-89.22% Return on Assets-19.99%Miscellaneous EmployeesN/A Outstanding Shares45,110,000Market Cap$469.60 million Next Earnings Date5/8/2019 (Estimated) OptionableOptionable CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions What is CytomX Therapeutics' stock symbol? CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX." How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics Inc (NASDAQ:CTMX) released its quarterly earnings results on Wednesday, February, 27th. The biotechnology company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.23. The biotechnology company had revenue of $11.47 million for the quarter, compared to analysts' expectations of $13.48 million. CytomX Therapeutics had a negative return on equity of 89.22% and a negative net margin of 142.19%. View CytomX Therapeutics' Earnings History. When is CytomX Therapeutics' next earnings date? CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for CytomX Therapeutics. What price target have analysts set for CTMX? 8 brokerages have issued 12-month target prices for CytomX Therapeutics' shares. Their forecasts range from $13.24 to $40.00. On average, they expect CytomX Therapeutics' stock price to reach $23.6057 in the next year. This suggests a possible upside of 126.8% from the stock's current price. View Analyst Price Targets for CytomX Therapeutics. What is the consensus analysts' recommendation for CytomX Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytomX Therapeutics. What are Wall Street analysts saying about CytomX Therapeutics stock? Here are some recent quotes from research analysts about CytomX Therapeutics stock: 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (3/5/2019) 2. HC Wainwright analysts commented, "We have valued CytomX Therapeutics based on a discounted cash flow (DCF) assessment that is driven by a combination of CX-072 future sales and BMS-986249 future royalties on net sales." (9/13/2018) Has CytomX Therapeutics been receiving favorable news coverage? Media stories about CTMX stock have been trending neutral this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. CytomX Therapeutics earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the stock's share price in the near term. Who are some of CytomX Therapeutics' key competitors? Some companies that are related to CytomX Therapeutics include Endo International (ENDP), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX), Enanta Pharmaceuticals (ENTA), Mallinckrodt (MNK), Zai Lab (ZLAB), Xencor (XNCR), Arrowhead Pharmaceuticals (ARWR), Myovant Sciences (MYOV), Pacira Pharmaceuticals (PCRX), Allakos (ALLK), Opko Health (OPK), Puma Biotechnology (PBYI), Prestige Consumer Healthcare (PBH) and Wave Life Sciences (WVE). What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Alibaba Group (BABA), Bausch Health Companies (BHC), Johnson & Johnson (JNJ), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA), TherapeuticsMD (TXMD), AbbVie (ABBV), Dynavax Technologies (DVAX) and Gilead Sciences (GILD). Who are CytomX Therapeutics' key executives? CytomX Therapeutics' management team includes the folowing people: Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 52)Mr. Debanjan Ray, CFO & Head of Corp. Devel. (Age 41)Dr. Rachel Wallach Humphrey, Chief Medical Officer (Age 58)Dr. Hoyoung Huh, Special Advisor to Chief Exec. Officer (Age 50)Dr. W. Michael Kavanaugh, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 63) Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (13.16%), BlackRock Inc. (8.58%), Perceptive Advisors LLC (6.47%), Victory Capital Management Inc. (2.04%), RTW Investments LP (2.02%) and Geode Capital Management LLC (1.26%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Kevin P Starr, Lloyd A Rowland, Rachel Humphrey, Robert I Tepper, Rock Ventures Lp Third, Sean A Mccarthy and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics. Which major investors are selling CytomX Therapeutics stock? CTMX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Two Sigma Investments LP, Barclays PLC, Hamilton Lane Advisors LLC, Two Sigma Advisers LP, MetLife Investment Advisors LLC and Squarepoint Ops LLC. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray, Frederick W Gluck and Sean A Mccarthy. View Insider Buying and Selling for CytomX Therapeutics. Which major investors are buying CytomX Therapeutics stock? CTMX stock was acquired by a variety of institutional investors in the last quarter, including RTW Investments LP, Perceptive Advisors LLC, Artal Group S.A., Candriam Luxembourg S.C.A., Citigroup Inc., United Services Automobile Association, Geode Capital Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for CytomX Therapeutics. How do I buy shares of CytomX Therapeutics? Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is CytomX Therapeutics' stock price today? One share of CTMX stock can currently be purchased for approximately $10.41. How big of a company is CytomX Therapeutics? CytomX Therapeutics has a market capitalization of $469.60 million and generates $59.50 million in revenue each year. The biotechnology company earns $-84,600,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. What is CytomX Therapeutics' official website? The official website for CytomX Therapeutics is http://www.cytomx.com. How can I contact CytomX Therapeutics? CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected] MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 247 (Vote Outperform)Underperform Votes: 185 (Vote Underperform)Total Votes: 432MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/24/2019 by MarketBeat.com StaffFeatured Article: Why is the price-sales ratio important?